RXi Pharmaceuticals Corporation announced that H. Paul Dorman and Curtis Lockshin, Ph.D. have been appointed to the company's Board of Directors. Mr. Dorman and Dr. Lockshin both bring significant industry experience that will be instrumental to supporting RXi's growth and development initiatives. Mr. Dorman brings nearly three decades of executive experience in the pharmaceutical industry with Johnson & Johnson and Baxter, in various leadership roles, to RXi.

He currently serves as Chairman and CEO of DFB Pharmaceuticals. Dr. Lockshin comes to RXi providing exceptional industry insight and functional, hands-on experience. Most recently, he has been an Independent Pharmaceutical & Life Sciences Consultant for OPKO Health Inc. Prior to this role, Dr. Lockshin served as Vice President, Corporate R&D Initiatives for OPKO Health Inc., with operational responsibilities inside several of OPKO's R&D units.

He currently serves as a Director of the Ruth K. Broad Biomedical Research Foundation. He previously served as a Director of Sorrento Therapeutics and Winston Pharmaceuticals.